title: Adoptive T Cell Therapy Targeting CD1 and MR1.
abstract: Adoptive T cell immunotherapy has demonstrated clinically relevant efficacy in treating malignant and infectious diseases. However, much of these therapies have been focused on enhancing, or generating de novo, effector functions of conventional T cells recognizing HLA molecules. Given the heterogeneity of HLA alleles, mismatched patients are ineligible for current HLA-restricted adoptive T cell therapies. CD1 and MR1 are class I-like monomorphic molecules and their restricted T cells possess unique T cell receptor specificity against entirely different classes of antigens. CD1 and MR1 molecules present lipid and vitamin B metabolite antigens, respectively, and offer a new front of targets for T cell therapies. This review will cover the recent progress in the basic research of CD1, MR1, and their restricted T cells that possess translational potential.
authors.affiliation: Department of Immunology, University of Toronto , Toronto, ON , Canada ; Princess Margaret Cancer Centre, University Health Network , Toronto, ON , Canada.
authors.forename: Tingxi
authors.initials: T
authors.lastname: Guo
authors.affiliation: Princess Margaret Cancer Centre, University Health Network , Toronto, ON , Canada.
authors.forename: Kenji
authors.initials: K
authors.lastname: Chamoto
authors.affiliation: Department of Immunology, University of Toronto , Toronto, ON , Canada ; Princess Margaret Cancer Centre, University Health Network , Toronto, ON , Canada.
authors.forename: Naoto
authors.initials: N
authors.lastname: Hirano
keywords: CD1; MAIT; MR1; NKT; T cell; adoptive cell transfer; immunotherapy